NASDAQ:KYTX Kyverna Therapeutics Q4 2024 Earnings Report $3.07 +0.16 (+5.50%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$3.22 +0.15 (+4.89%) As of 06/20/2025 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Kyverna Therapeutics EPS ResultsActual EPS-$0.88Consensus EPS -$0.87Beat/MissMissed by -$0.01One Year Ago EPSN/AKyverna Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AKyverna Therapeutics Announcement DetailsQuarterQ4 2024Date3/27/2025TimeBefore Market OpensConference Call DateThursday, March 27, 2025Conference Call Time4:00PM ETUpcoming EarningsKyverna Therapeutics' Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled on Tuesday, August 12, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesReportAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsReportAnnual report(10-K) Kyverna Therapeutics Earnings HeadlinesKyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Recommendation of "Buy" by AnalystsJune 15, 2025 | americanbankingnews.com3 Promising Penny Stocks With Market Caps Over $100MJune 10, 2025 | finance.yahoo.comThe IRS Loophole That Lets You Own Gold Tax-FreeWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? No gimmicks. No shady tricks. Just a powerful IRS-approved loophole that most Americans have never heard of. It's called a Self-Directed Gold IRA, and it's quietly becoming the go-to wealth protection strategy for people who see the writing on the wall. When you take the next step, you could qualify for up to $10,000 in FREE GOLD & SILVER with your purchase of a qualified account.June 21, 2025 | Advantage Gold (Ad)Kyverna Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | prnewswire.comHC Wainwright & Co. Upgrades Kyverna Therapeutics (KYTX)May 27, 2025 | msn.comWith 40% ownership, Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has piqued the interest of institutional investorsMay 16, 2025 | finance.yahoo.comSee More Kyverna Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kyverna Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kyverna Therapeutics and other key companies, straight to your email. Email Address About Kyverna TherapeuticsKyverna Therapeutics (NASDAQ:KYTX), a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.View Kyverna Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Broadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Upcoming Earnings FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025)Bank of America (7/14/2025)Wells Fargo & Company (7/14/2025)JPMorgan Chase & Co. (7/14/2025)Interactive Brokers Group (7/15/2025)America Movil (7/15/2025)Citigroup (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
